The earnings call reflects solid execution and growth in key segments like Life Sciences, particularly in process chromatography and the successful expansion of the ddPCR portfolio. However, challenges remain, particularly with gross margin declines, increased expenses, and ongoing softness in certain markets. Despite these lowlights, the positive developments and strategic advancements present a balanced outlook.

Company Guidance -

Q3 2025

During the Bio-Rad Second Quarter 2025 Results Conference Call, the company provided updated guidance reflecting their financial performance and strategic developments. Bio-Rad reported a 2.1% increase in net sales to approximately $652 million compared to Q2 2024, driven by strong double-digit growth in their process chromatography segment. The Life Sciences Group showed a 4.9% increase in sales, while the Clinical Diagnostics Group remained stable with $389 million in sales. Operating margins exceeded expectations, aided by product mix and cost control measures. The company completed the acquisition of Stilla Technologies, enhancing their Droplet Digital PCR portfolio, which saw high single-digit revenue growth. Bio-Rad raised its full-year 2025 guidance, now anticipating currency-neutral revenue growth of flat to 1%, with Life Sciences expected to grow flat to 1% and Diagnostics by 0.5% to 1.5%. The updated outlook considers reduced tariff impacts, projecting a full-year non-GAAP operating margin between 12% and 13%, up from previous estimates.

Revenue and Operating Margin Exceed Expectations

Both revenue and operating margin exceeded consensus expectations for the second quarter of 2025, demonstrating strong portfolio performance and team discipline. Revenue was approximately $652 million, a 2.1% increase from the previous year.

Life Science Segment Growth

The Life Science segment saw a 4.9% increase in sales, primarily driven by growth in process chromatography and food safety products. The process chromatography business experienced double-digit year-over-year growth.

Droplet Digital PCR (ddPCR) Advancements

The development of the QX Continuum platform was completed, and the acquisition of Stilla Technologies was closed. The rebranded QX700 Series ddPCR instruments were launched.

Clinical Diagnostics Stability

The Clinical Diagnostics business showed stability with sales of approximately $389 million, supported by increased demand for quality control and immunology products.

Improved Free Cash Flow

Free cash flow for the second quarter was $71 million, up from $55 million in Q2 2024, with a year-to-date free cash flow to non-GAAP net income conversion ratio of 117%.

Bio-Rad Laboratories (BIO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BIO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	1.76 / -	2.01	―	―	―
Jul 31, 2025	2025 (Q2)	1.73 / 2.61	3.11	-16.08% (-0.50)
May 01, 2025	2025 (Q1)	1.81 / 2.54	2.29	10.92% (+0.25)	―
Feb 13, 2025	2024 (Q4)	2.87 / 2.90	3.1	-6.45% (-0.20)	―
Oct 30, 2024	2024 (Q3)	1.16 / 2.01	2.33	-13.73% (-0.32)	―
Aug 01, 2024	2024 (Q2)	2.02 / 3.11	3	3.67% (+0.11)	―
May 07, 2024	2024 (Q1)	2.15 / 2.29	3.34	-31.44% (-1.05)	―
Feb 15, 2024	2023 (Q4)	2.82 / 3.10	3.31	-6.34% (-0.21)	―
Oct 26, 2023	2023 (Q3)	2.78 / 2.33	2.6	-10.38% (-0.27)	―
Aug 03, 2023	2023 (Q2)	2.68 / 3.00	3.38	-11.24% (-0.38)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BIO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$241.95	―	―
May 01, 2025	$240.43	$236.34	-1.70%
Feb 13, 2025	$306.36	$277.16	-9.53%
Oct 30, 2024	$330.58	$358.19	+8.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bio-Rad Laboratories (BIO) report earnings?

Bio-Rad Laboratories (BIO) is schdueled to report earning on Oct 23, 2025, After Close (Confirmed).

What is Bio-Rad Laboratories (BIO) earnings time?

Bio-Rad Laboratories (BIO) earnings time is at Oct 23, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BIO EPS forecast?

BIO EPS forecast for the fiscal quarter 2025 (Q3) is 1.77.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing